


# CLEAR Wisdom

#ACC19



AMERICAN  
COLLEGE of  
CARDIOLOGY

**Trial Description:** Patients with known ASCVD/heterozygous familial hypercholesterolemia (FH) on intensive/maximum-tolerated statin therapy with LDL-C > goal were randomized 2:1 to either bempedoic acid 180 mg daily or placebo and followed for 52 weeks.



## RESULTS

- Primary endpoint: change in LDL-C from baseline for bempedoic acid vs. placebo: -15.1% vs. 2.4%,  $p < 0.001$
- Change in hsCRP from baseline at week 12: -18.7% vs. -9.4%,  $p = 0.039$
- 5-point MACE: 6.1% vs. 8.2%,  $p > 0.05$ ; MI: 1.1% vs. 3.5%

## CONCLUSIONS

- Bempedoic acid is safe and effective in reducing LDL-C compared with placebo among patients with ASCVD or heterogeneous FH on maximum-tolerated statin therapy
- No difference was noted for clinical outcomes – trial was not powered for this

Presented by Dr. Anne C. Goldberg at ACC 2019